Agaricus blazei-Based Mushroom Extract Supplementation to Birch Allergic Blood Donors: A Randomized Clinical Trial

Mahmood, Faiza; Hetland, Geir; Nentwich, Ivo; Mirlashari, Mohammad Reza; Ghiasvand, Reza; Nissen‐Meyer, Lise Sofie Haug

doi:10.3390/nu11102339

Cited by 12 publications

(10 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Examples of diseases with beneficial effect of these mushrooms are as follows: Alzheimer's disease, 86 IBD, 9,10 bacterial infections, 39,40 malaria, 47 and allergy and asthma. 13 This is supported by AbM's ability to activate the alternative pathway of complement. 87 Also, there is new evidence for intracellular complementthe complosome-that is thought to be involved in immune cell regulation and metabolism in T cells and monocytes.…”

Section: Immunomodulation and Defence At The Mucosamentioning

confidence: 98%

“…In another placebo-controlled RCT with IBD patients, 9,10 Therkelsen et al showed that Andosan™ given orally for 3 weeks reduced symptoms and increased quality of life especially of the patients with ulcerative colitis, 9 by an anti-inflammatory mechanism. 13 In a rat IBD model, also HE extract and isolated polysaccharide were shown to improve IBD-induced colonic mucosa damage by reducing MPO activity. 54 In colonic mucosa, also NF Κ B and TNFα expression was decreased and T cells were activated and growth of beneficial gut bacteria was promoted.…”

Section: Effects Of Abm He and Gfmentioning

confidence: 99%

“…In addition, in a placebo-controlled RCT in individuals with pollen allergy and asthma, Andosan™ supplementation before the pollen season resulted in decreased symptoms, medication, specific plasma IgE levels and basophil sensitivity, owing to a skewing of Th1/Th2 cells towards the Th1 phenotype. 13 The Th1 response is besides its induction of antitumoral and anti-allergic activity, also driving an antiviral immune response as discussed.…”

Section: Infectionmentioning

confidence: 99%

“…8 It has been used in three placebo-controlled randomized clinical trials as supplement to regular treatment for inflammatory bowel disease (IBD); ulcerative colitis (UC) (50 patients) and Crohn's disease (CD) (50 patients), [9][10][11] multiple myeloma (MM) 12 (40 patients) and pollen allergy and asthma 13 (60 blood donors) without adverse effects. It reduced proinflammatory cytokines and improved symptoms and quality of life in IBD patients, [9][10][11] reduced allergy and asthma symptoms, specific IgE and basophil sensitivity in allergics, 13 and increased IL-1 receptor antagonist (IL-1ra), IL-7, T regulatory cells, dendritic cells (DCs) and expression of Ig, Killer Ig receptors (KIRs) and HLA genes in MM patients. 12 Moreover, since the beginning of this millennium there have been quite a few other reports on antimicrobial ( Table 1, 2) and anti-inflammatory (Table 3) effects of medicinal mushrooms such as AbM, HE and GF.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Can medicinal mushrooms have prophylactic or therapeutic effect against COVID‐19 and its pneumonic superinfection and complicating inflammation?

et al. 2020

Self Cite

View full text Add to dashboard Cite

Medicinal mushrooms have documented effects against different diseases, including infections and inflammatory disorders. The related Basidiomycota Agaricus blaz ei Murill (AbM), Hericium erinaceus (HE), and Grifola frondosa (GF) have been shown to exert antimicrobial activity against viral agents, Gram‐positive and Gram‐negative bacteria, and parasites in vitro and in vivo. Since the mechanism is immunomodulatory and not antibiotical, the mushrooms should be active against multi‐drug resistant microbes as well. Moreover, since these Basidiomycota also have anti‐inflammatory properties, they may be suited for treatment of the severe lung inflammation that often follows COVID‐19 infection. An AbM‐based mushroom extract (Andosan™), also containing HE and GF, has been shown to significantly reduce bacteraemia and increase survival in mice with pneumococcal sepsis, and to improve symptoms and quality of life in IBD patients via an anti‐inflammatory effect. Hence, such mushroom extracts could have prophylactic or therapeutic effect against the pneumonic superinfection and severe lung inflammation that often complicates COVID‐19 infection. Here, we review antimicrobial and anti‐inflammatory properties of AbM, HE and GF mushrooms, which could be used for the battle against COVID‐19.

show abstract

Section: Immunomodulation and Defence At The Mucosamentioning

confidence: 98%

Section: Effects Of Abm He and Gfmentioning

confidence: 99%

Section: Infectionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Can medicinal mushrooms have prophylactic or therapeutic effect against COVID‐19 and its pneumonic superinfection and complicating inflammation?

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recently, our group performed a placebo-controlled randomized clinical study in which blood donors with self-reported and specific IgE-confirmed birch allergy and asthma, given Andosan TM orally for 2 months before the pollen season, had less general allergy and asthma ailments and used less medication. This was due to reduced specific IgE levels and reduced mast cell sensitization, as demonstrated indirectly by the basophil activation test [95]. [97] Abbreviations: immunoglobulin (Ig), ovalbumin (OVA), atopic dermatitis (AD).…”

Section: Antiallergic Effects Of Abm and Gf Extractsmentioning

confidence: 99%

Antitumor, Anti-inflammatory and Antiallergic Effects of Agaricus blazei Mushroom Extract and the Related Medicinal Basidiomycetes Mushrooms, Hericium erinaceus and Grifola frondosa: A Review of Preclinical and Clinical Studies

et al. 2020

Self Cite

View full text Add to dashboard Cite

Since the 1980s, medicinal effects have been documented in scientific studies with the related Basidiomycota mushrooms Agaricus blazei Murill (AbM), Hericium erinaceus (HE) and Grifola frondosa (GF) from Brazilian and Eastern traditional medicine. Special focus has been on their antitumor effects, but the mushrooms’ anti-inflammatory and antiallergic properties have also been investigated. The antitumor mechanisms were either direct tumor attack, e.g., apoptosis and metastatic suppression, or indirect defense, e.g., inhibited tumor neovascularization and T helper cell (Th) 1 immune response. The anti-inflammatory mechanisms were a reduction in proinflammatory cytokines, oxidative stress and changed gut microbiota, and the antiallergic mechanism was amelioration of a skewed Th1/Th2 balance. Since a predominant Th2 milieu is also found in cancer, which quite often is caused by a local chronic inflammation, the three conditions—tumor, inflammation and allergy—seem to be linked. Further mechanisms for HE were increased nerve and beneficial gut microbiota growth, and oxidative stress regulation. The medicinal mushrooms AbM, HE and GF appear to be safe, and can, in fact, increase longevity in animal models, possibly due to reduced tumorigenesis and oxidation. This article reviews preclinical and clinical findings with these mushrooms and the mechanisms behind them.

show abstract

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Wise

Damask

Roland

et al. 2023

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

Background In the 5 years that have passed since the publication of the 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis 2018), the literature has expanded substantially. The ICAR‐Allergic Rhinitis 2023 update presents 144 individual topics on allergic rhinitis (AR), expanded by over 40 topics from the 2018 document. Originally presented topics from 2018 have also been reviewed and updated. The executive summary highlights key evidence‐based findings and recommendation from the full document. Methods ICAR‐Allergic Rhinitis 2023 employed established evidence‐based review with recommendation (EBRR) methodology to individually evaluate each topic. Stepwise iterative peer review and consensus was performed for each topic. The final document was then collated and includes the results of this work. Results ICAR‐Allergic Rhinitis 2023 includes 10 major content areas and 144 individual topics related to AR. For a substantial proportion of topics included, an aggregate grade of evidence is presented, which is determined by collating the levels of evidence for each available study identified in the literature. For topics in which a diagnostic or therapeutic intervention is considered, a recommendation summary is presented, which considers the aggregate grade of evidence, benefit, harm, and cost. Conclusion The ICAR‐Allergic Rhinitis 2023 update provides a comprehensive evaluation of AR and the currently available evidence. It is this evidence that contributes to our current knowledge base and recommendations for patient evaluation and treatment.

show abstract

Agaricus blazei-Based Mushroom Extract Supplementation to Birch Allergic Blood Donors: A Randomized Clinical Trial

Cited by 12 publications

References 43 publications

Can medicinal mushrooms have prophylactic or therapeutic effect against COVID‐19 and its pneumonic superinfection and complicating inflammation?

Can medicinal mushrooms have prophylactic or therapeutic effect against COVID‐19 and its pneumonic superinfection and complicating inflammation?

Antitumor, Anti-inflammatory and Antiallergic Effects of Agaricus blazei Mushroom Extract and the Related Medicinal Basidiomycetes Mushrooms, Hericium erinaceus and Grifola frondosa: A Review of Preclinical and Clinical Studies

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Contact Info

Product

Resources

About